-+ 0.00%
-+ 0.00%
-+ 0.00%

Health Canada expands Bayer’s Lynkuet label to treat hot flashes tied to breast cancer endocrine therapy

PUBT·08/17/2026 18:21:26
Listen to the news
Health Canada expands Bayer’s Lynkuet label to treat hot flashes tied to breast cancer endocrine therapy
  • Health Canada expanded Bayer AG’s market authorization for LYNKUET (elinzanetant) to treat moderate-to-severe vasomotor symptoms caused by breast cancer AET.
  • Decision makes LYNKUET the first approved option in Canada for this AET-related hot flash and night sweat population.
  • Authorization follows Health Canada’s July 2025 clearance for LYNKUET in moderate-to-severe menopausal vasomotor symptoms.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bayer AG published the original content used to generate this news brief via Business Wire (Ref. ID: 202608171421BIZWIRE_USPR_____20260817_BW156386) on August 17, 2026, and is solely responsible for the information contained therein.